(NASDAQ: BEAM) Beam Therapeutics's forecast annual revenue growth rate of -0.02% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 106.08%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 24.86%.
Beam Therapeutics's revenue in 2025 is $60,272,000.On average, 17 Wall Street analysts forecast BEAM's revenue for 2025 to be $4,324,271,963, with the lowest BEAM revenue forecast at $1,586,220,568, and the highest BEAM revenue forecast at $6,999,906,389. On average, 17 Wall Street analysts forecast BEAM's revenue for 2026 to be $5,146,314,587, with the lowest BEAM revenue forecast at $2,974,163,564, and the highest BEAM revenue forecast at $11,684,214,003.
In 2027, BEAM is forecast to generate $6,123,640,920 in revenue, with the lowest revenue forecast at $2,974,163,564 and the highest revenue forecast at $12,746,415,276.